On June 16, 2026, stockholders approved three proposals: the issuance of shares upon the exercise of warrants (including those exceeding 19.99% of outstanding common stock as of April 22, 2026) at an exercise price of $0.00001 per share, the adjustment of the number of shares issuable upon warrant exercise, and voluntary adjustments to the warrant exercise price. The company operates in the biopharmaceutical industry and develops therapeutic products.
